www.achaten-suisse.com
- US Toll free:
- Regular US:
- UK:
- Categories list
-
- HIV
- Alzheimer's And Parkinson's
- Erectile Dysfunction
- Surgery
- Cardiovascular Diseases
- Eye Care
- Urinary Tract
- Antiallergic
- Skin Care
- Obesity
- Respiratory Tract
- Cancer
- Analgesics
- Mental Disorders
- Alcoholism
- Gastrointestinal Tract
- Diabetes
- Men's Health
- Antiparasitic
- Arthritis
- Osteoporosis
- Anticonvulsants
- Cholesterol
- Hypertension
- Antifungals
- Stop Smoking
- Birth Control
- Women's Health
- Antibiotics
- Migraine
- Diuretics
- Antidepressants
- Asthma
- Neurological Disorders
- Anti-inflammatories
- Antivirals
- Muscle Relaxants
Generic Lamivudine zidovudine - Combivir, Epivir, Retrovir
Get Combivir
Lamivudine - Zidovudine 150mg + 300mg
Generic Combivir is in a group of medicines called reverse transcriptase inhibitors. It is used for treating HIV infection in combination with other medicines.
£0.92
Buy now!
Get Epivir
Generic Epivir is used for treating HIV infection in combination with other medicines.
£1.11
Buy now!
Get Retrovir
Generic Retrovir is used for treating HIV infection when used along with other medicines. It is also used with other medicines to help prevent women from passing the HIV virus to the fetus during pregnancy.
£0.75
Buy now!
Choose Your language:
- Testimonials
-
Yes I have received the product. It came just as you said it would. I'm very pleased with the delivery. I have not tried the product yet but will soon. If it is as good as your delivery I will be most happy and you will have a customer for a very long time. - Thank you
Read more »
-
- This RSS feed URL is deprecated
- This RSS feed URL is deprecated, please update
- Landmark Phase III studies for dolutegravir and lamivudine - The Pharma Letter
- The Pharma LetterLandmark Phase III studies for dolutegravir and lamivudineThe Pharma LetterViiV Healthcare, the specialty HIV/AIDS company majority owned by GlaxoSmithKline (LSE: GSK), today announced positive headline results from its Phase III GEMINI study program
- ViiV has 'another formidable asset' in rivalry with Gilead - The Pharma Letter
- The Pharma LetterViiV has 'another formidable asset' in rivalry with GileadThe Pharma LetterClaims by ViiV Healthcare's chief executive Deborah Waterhouse (pictured above) that her company is doing more than just playing second fiddle to US biotech Gilead Science (Nasdaq: GILD) in the HIV space have been backed up by an analyst at
- Antiretroviral Contraindications and Drug Interactions - Infectious Disease Advisor
- Antiretroviral Contraindications and Drug InteractionsInfectious Disease AdvisorSevere renal impairment or ESRD (CrCl
- China Biopharma Company Risks De-Listing After Data Fraud - BioSpace (press release) (blog)
- BioSpace (press release) (blog)China Biopharma Company Risks De-Listing After Data FraudBioSpace (press release) (blog)The report stated that the WHO Prequalification Team (PQT) inspected the company's Chennai, India facility between October 13 and 17, 2014, focusing on Study No
 |
Bookmark this site |
|---|
 |
Subscribe to the News |
|---|
